Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer

Anne E. O’Shea _, Guy T. Clifton and George E. Peoples

PDF  |  How to cite  |  Order a Reprint

Oncotarget. 2021; 12:2318-2319. https://doi.org/10.18632/oncotarget.27998

Metrics: PDF 616 views  |   ?  

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27998